RT Journal
T1 Clarification of conflict of interest disclosures in: A proposed model for initial assessment and management of acute heart failure syndromes
JF JAMA
JO JAMA
YR 2012
FD February 8
VO 307
IS 6
SP 563
OP 563
DO 10.1001/jama.2012.113
UL http://dx.doi.org/10.1001/jama.2012.113
AB 
Clarification of Conflict of Interest Disclosures:  In the Editorial entitled “Hospitalizations for Heart Failure in the United States—A Sign of Hope,” published in the October 19, 2011, issue of JAMA (2011;306[15]:1705-1706), and in the Commentary entitled “A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes,” published in the April 27, 2011, issue of JAMA (2011;305[16]:1702-1703), the conflict of interest disclosure information for Dr Braunwald should have read as follows: Dr Braunwald reported receiving research support from Merck, AstraZeneca, Johnson & Johnson, Beckman Coulter, Eli Lilly, Roche Diagnostics, sanofi-aventis, Daiichi Sankyo, GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer as well as participating in symposia, advisory board meetings, and/or consultancies for the following companies: Eli Lilly, Merck, Genzyme, Amorcyte, CVRx (no compensation), The Medicines Company, CV Therapeutics, Daiichi Sankyo, MC Communications, Ortho McNeil, Ikaria, Menarini International, CardioRentis, and sanofi-aventis. Also in the Commentary, the conflict of interest disclosure for Dr Gheorghiade should have read as follows: Dr Gheorghiade reported that he received consulting fees from Bayer, Novartis, Sigma Tau, Johnson & Johnson, Takeda, Otsuka, and Medtronic. These 2 articles were corrected online. A letter regarding the differences in Dr Braunwald's conflict of interest disclosures appears in this issue.